Lost money in Unicycive Therapeutics, Inc. stock? You may be able to recover your losses.
Patel v. Unicycive Therapeutics, Inc., No. 3:26-cv-09559 (N.D. Cal.)
A federal securities class action has been filed on behalf of Unicycive Therapeutics, Inc. (UNCY) investors. Find out in about 30 seconds whether you may be eligible to participate, at no cost.
- No cost to participate
- No fee unless investors recover
- Talk to a real person, not a call center
- Lead plaintiff deadline
- November 2, 2026
- 34 days remaining
- Class period
- Dec 29, 2025 – Jun 29, 2026
- Eligible purchases fall between these dates
What happened to UNCY
About this case
On June 30, 2026, Unicycive disclosed that the FDA had issued a second Complete Response Letter, declining to approve OLC based on the same manufacturing deficiencies identified a year earlier. The company also stated that it understood the FDA had not yet inspected the manufacturer’s facility during its review of the resubmitted application. On this news, Unicycive’s stock fell approximately 39%.
The class action alleges that Unicycive Therapeutics and certain of its executives misled investors about the prospects for FDA approval of its drug candidate, OLC. According to the complaint, the company had not inspected its third-party manufacturer’s facility or audited its compliance with manufacturing standards, leaving it without a reasonable basis to believe previously identified FDA deficiencies had been resolved. The lawsuit alleges that Unicycive failed to disclose the resulting risk of further regulatory delays.
The allegations, in plain terms
- June 2025The company disclosed that the FDA issued a Complete Response Letter for its OLC New Drug Application, citing deficiencies at a third-party manufacturing vendor.
- Dec. 29, 2025Start of the class period. The investigation concerns whether Unicycive made false or misleading statements, or failed to disclose material information, about the FDA's review of its resubmitted OLC application.
- June 30, 2026The company disclosed that the FDA issued a second Complete Response Letter based on the same third-party manufacturing deficiencies flagged in the June 2025 letter, and that it understood the FDA had not yet inspected the manufacturing vendor during the resubmission review. The stock fell about 39% that day.
- TodayBlock & Leviton is investigating whether Unicycive misled investors regarding the FDA's review of its OLC New Drug Application. No case has been filed and no court has made any findings.
Summarizes allegations in the complaint — they are not findings of any court.
We screen hundreds of stock drops every year and file only a handful. If we're investigating this one, it's because we believe in it.
Block & Leviton is run by the partners whose names are on the door — and our clients deal with them directly, whatever the size of the loss. That's the point of staying small.
A dismissed case turned into a $150 million record.* A recovery from a company that went bankrupt. We build cases to go the distance — not to settle cheap.
* Subject to court approval. Prior results do not guarantee a similar outcome.
Who we are — and why we're involved
Block & Leviton represents investors. We never represent the companies we investigate. When a company's own disclosures reveal that shareholders were misled, we investigate and bring claims to recover those losses.
Our clients are people like you: individual investors, retirees, and pension funds harmed when the truth comes out and a stock falls. There is no cost to you to participate, and attorneys' fees are paid only out of a recovery approved by the court.
Who you'll be dealing with
Jake Walker
Represents investors in securities class actions nationwide.
Your first call will usually be with David White, our investor liaison — and our partners are directly involved in every case.
A record courts have trusted
NextEra Energy — $150 million
The district court dismissed the case. We appealed — and won a unanimous reversal in the Eleventh Circuit Court of Appeals. The result: a $150 million settlement — the largest securities class action settlement in the Southern District of Florida in more than 30 years.*
Dismissed — then revived when we persuaded the court to reconsider its own judgment. Settled in 2026.
Recovered for investors even after Tricida itself went bankrupt.
Federal courts have appointed Block & Leviton lead counsel in securities class actions on behalf of investors nationwide. Our attorneys have recovered billions of dollars for investors, retirees, and pension funds.
* Subject to court approval. Prior results do not guarantee a similar outcome. Attorney advertising.
Common questions
Will this cost me anything?
No. There is no cost to submit your information, no cost to participate, and no out-of-pocket cost ever. If there's a recovery, attorneys' fees are paid from it and must be approved by the court.
I'm already part of the class automatically — so why submit my information?
It's true: if you bought UNCY during the class period, you're a class member whether or not you contact anyone. Submitting your information lets us evaluate your specific losses, keep you informed as the case develops, and tell you whether you may benefit from a larger role in the case.
What is a lead plaintiff?
The lead plaintiff is an investor the court appoints to represent the class, typically someone with a significant loss. Lead plaintiffs oversee the litigation on behalf of everyone and are entitled to seek reimbursement for their time. The deadline to seek appointment in this case is November 2, 2026.
I sold my shares after the drop — am I still eligible?
Possibly, yes. What generally matters is that you purchased shares during the class period and were harmed by the decline. Whether you still hold shares today doesn't necessarily disqualify you — submit your details and we'll evaluate your situation.
Does submitting this form make you my lawyers?
No — and that's a protection for you. Submitting the form only lets us evaluate your potential claim, at no cost. If we determine we can help and you decide to move forward, we'll send you a written retainer agreement that spells out the relationship, the contingency fee, and your rights. You're never committed to anything until you've read and signed it.
What happens after I submit the form?
Our team reviews your submission — usually within one business day. David, our investor liaison, will reach out by phone or email, and our partners are directly involved in every case. You're never obligated to do anything.
Attorney advertising. Prior results do not guarantee a similar outcome. Block & Leviton LLP is responsible for the content of this page. Submitting information through this page does not create an attorney-client relationship.